Elanco
ELAN NYSE· Pharmaceuticals
Last close · Oct 26, 2026
$22.96
KIRA · Stoqly’s AI analyst, in plain words
- Elanco had $4.7B of revenue in fiscal 2025, up 6.2% on the year before. Over five years, revenue changed +7.6% a year on average.
- Elanco lost $232M in fiscal 2025.
- Free cash flow was $284M in fiscal 2025, 6.0% of revenue.
- Elanco returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count fell 0.2%.
- Elanco owes $3.5B more than it holds in cash, about 5.2 years of operating profit.
Market cap
$11.6B
P/E
—
Revenue
$4.7B
Net income
−$232M
Free cash flow
$284M
Operating margin
—
Elanco in 30 seconds · fiscal 2025
Are sales growing?
+6.2%
Yes. Sales grew 6.2% last year.
Does it make a profit?
−4.9%
No. It lost money last year.
Does profit turn into cash?
6.0%
Partly. 6.0% of sales ends up as free cash.
Is debt under control?
5.2x
Heavy. Repaying its debt would take 5.2 years of operating profit.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
What Elanco does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- Elanco Animal Health Incorporated
- CIK
- 0001739104
Elanco · ELAN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $4.8B | $4.4B | $4.4B | $4.4B | $4.7B |
| Revenue growth | 45.6% | −7.4% | 0.1% | 0.5% | 6.2% |
| Gross margin | 55.3% | 56.6% | 56.3% | 54.9% | 55.0% |
| Net income | −$483M | −$78.0M | −$1.2B | $338M | −$232M |
| Net margin | −10.1% | −1.8% | −27.9% | 7.6% | −4.9% |
| Diluted EPS | −$0.99 | −$0.16 | −$2.50 | $0.68 | −$0.47 |
| Cash | |||||
| Cash from operations | $483M | $452M | $271M | $541M | $560M |
| Capital expenditure | $159M | $171M | $140M | $147M | $276M |
| Free cash flow | $324M | $281M | $131M | $394M | $284M |
| FCF margin | 6.8% | 6.4% | 3.0% | 8.9% | 6.0% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share count change | 10.4% | 0.2% | 0.8% | 1.0% | −0.2% |
| Debt and strength | |||||
| Cash and short-term investments | $638M | $345M | $352M | $468M | $545M |
| Debt incl. finance leases | $6.3B | $5.8B | $5.8B | $4.3B | $4.0B |
| Shareholders' equity | $7.5B | $7.3B | $6.2B | $6.1B | $6.5B |
| Net debt / EBITDA | 14.9x | 6.5x | — | 2.7x | 5.2x |
| Current ratio | 2.0x | 1.9x | 2.8x | 2.4x | 2.2x |
| Interest coverage | −1.4x | 0.7x | −3.3x | 2.7x | −0.1x |
| Returns and quality | |||||
| Return on capital | −1.9% | 1.0% | −5.9% | 5.0% | −0.1% |
| Return on equity | −6.1% | −1.1% | −18.2% | 5.5% | −3.7% |
| Piotroski F-score | 6 | 5 | 4 | 6 | 6 |
| Altman Z'' | 1.2 | 1.5 | 0.8 | 1.9 | 1.4 |
Insiders bought, 12 months
$2.6M
7 insiders
Insiders sold, 12 months
$0.1M
1 insider
Of sales under plans
100%
$0.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Elanco · ELAN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Elanco ELAN | $11.6B | 6.2% | — | 6.0% | −0.1% | — | 6 |
| Jazz Pharmaceuticals JAZZ | $14.3B | 4.9% | −10.1% | 30.4% | −4.2% | 14.1x | 4 |
| Amneal Pharmaceuticals AMRX | $6.9B | 8.1% | 13.1% | 8.9% | 16.1% | 42.9x | 7 |
| Zoetis ZTS | $33.8B | 2.3% | — | 24.1% | 29.3% | 13.3x | 8 |
| Bausch Health Companies BHC | $2.4B | 6.7% | 17.7% | 9.8% | 4.5% | — | 7 |
KIRA
At $22.96 a share, the company is worth $11.6B.
Elanco grew sales faster than 2 of its 4 similar companies.
Source: SEC EDGAR XBRL filings (CIK 0001739104). Data updated October 14, 2026. For information only — not investment advice. Check the original filings before relying on any figure.